Jefferies Financial Group’s BridgeBio Pharma BBIO Stock Holding History

Jefferies Financial Group’s Portfolio BBIO Stock Details BBIO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$11.4M	Buy	153,615 +71,315	+87%	+$4.99M	0.08%	228
2026 Q1	$6.11M	Sell	82,300 -117,700	-59%	-$8.53M	0.04%	300
2025 Q4	$15.3M	Buy	+200,000	New	+$13.1M	0.08%	239
2025 Q1	–	Sell	-185,000	Closed	-$5.08M	–	1628
2024 Q4	$5.08M	Buy	+185,000	New	+$4.78M	0.03%	360
2024 Q2	–	Sell	-61,907	Closed	-$1.91M	–	1418
2024 Q1	$1.91M	Sell	61,907 -41,840	-40%	-$1.42M	0.02%	607
2023 Q4	$4.19M	Buy	103,747 +44,558	+75%	+$1.34M	0.03%	448
2023 Q3	$1.56M	Sell	59,189 -213,049	-78%	-$6.05M	0.01%	691
2023 Q2	$4.68M	Buy	272,238 +111,868	+70%	+$1.68M	0.04%	383
2023 Q1	$2.66M	Buy	+160,370	New	+$1.87M	0.02%	559

Other funds holding BBIO

Jupiter Topco New York $245B AUM

KKRC

Kohlberg Kravis Roberts & Co New York $5.71B AUM 72.37% 1-Year Est. Return

FCM

Farallon Capital Management San Francisco, California $21.7B AUM 79.24% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Viking Global Investors Stamford, Connecticut $35.1B AUM 21.36% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

ACM

Aisling Capital Management New York $472M AUM 106.83% 1-Year Est. Return

Jefferies Financial Group's BBIO Position: Q2 2026 in Review

Jefferies Financial Group increased its BridgeBio Pharma (BBIO) stake by 87% in Q2 2026, buying an estimated $4.99M and bringing the position to 153,615 shares worth $11.4M. The position accounts for 0.08% of the portfolio, ranked #228.

Jefferies Financial Group first reported a position in BBIO in Q1 2023 and has held it in 9 quarters since. The position peaked at $15.3M in Q4 2025. 474 funds tracked by Wall St. Rank hold BBIO as of Q2 2026.

Jefferies Financial Group held 153,615 shares of BridgeBio Pharma worth $11.4M as of Q2 2026.
Jefferies Financial Group bought 71,315 BridgeBio Pharma shares in Q2 2026, an estimated $4.99M.
BridgeBio Pharma made up 0.08% of Jefferies Financial Group's portfolio in Q2 2026, its #228 holding.
Jefferies Financial Group first reported a position in BridgeBio Pharma in Q1 2023 and has held it in 9 quarters since.
Jefferies Financial Group's BridgeBio Pharma position peaked at $15.3M in Q4 2025.
474 funds tracked by Wall St. Rank held BridgeBio Pharma as of Q2 2026.

Based on Jefferies Financial Group's 13F filing for Q2 2026, filed 17 Aug 2026.